Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20376044 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2FDPSCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6900904 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2FDPSCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13417397 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2FDPSCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24928122 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2FDPSCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12259536 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2FDPSCYP1A2CYP3A4CYP2D6 | |
| Bromide SCHEMBL15157311 | 0.97 | SMN1; SMN2 (0.39) | SMN1; SMN2FDPSCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15157543 | 0.97 | SMN1; SMN2 (0.39) | SMN1; SMN2FDPSCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13256071 | 0.97 | SMN1; SMN2 (0.38) | SMN1; SMN2FDPS | |
| SCHEMBL13417351 | 0.97 | SMN1; SMN2 (0.38) | SMN1; SMN2FDPS | |
| SCHEMBL12257624 | 0.97 | SMN1; SMN2 (0.38) | SMN1; SMN2FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11083703-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11083703-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | SMN1; SMN2 1861/4885FDPS 6/4885CYP1A2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.